5.335
price down icon12.71%   -0.825
 
loading
전일 마감가:
$6.16
열려 있는:
$6.205
하루 거래량:
9.30M
Relative Volume:
3.06
시가총액:
$474.84M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+2.62%
1개월 성능:
+6.90%
6개월 성능:
+48.13%
1년 성능:
+153.64%
1일 변동 폭
Value
$5.18
$6.21
1주일 범위
Value
$5.18
$7.2904
52주 변동 폭
Value
$1.67
$7.2904

Atyr Pharma Inc Stock (ATYR) Company Profile

Name
명칭
Atyr Pharma Inc
Name
전화
(858) 731-8389
Name
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Name
직원
59
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
ATYR's Discussions on Twitter

ATYR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ATYR
Atyr Pharma Inc
5.335 518.90M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
467.40 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.91 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.69 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.00 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.31 31.54B 3.81B -644.79M -669.77M -6.24

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-18 개시 Leerink Partners Outperform
2025-01-06 개시 Cantor Fitzgerald Overweight
2024-10-04 개시 Wells Fargo Overweight
2024-09-05 개시 Jefferies Buy
2023-07-05 다운그레이드 Oppenheimer Outperform → Perform
2021-10-12 개시 RBC Capital Mkts Outperform
2021-09-21 개시 Piper Sandler Overweight
2021-05-10 개시 Laidlaw Buy
2020-08-17 업그레이드 H.C. Wainwright Neutral → Buy
2020-03-04 개시 ROTH Capital Buy
2020-03-02 개시 Oppenheimer Outperform
2018-02-14 다운그레이드 JP Morgan Neutral → Underweight
2017-09-07 개시 Piper Jaffray Overweight
2016-12-13 다운그레이드 JP Morgan Overweight → Neutral
2015-12-16 개시 Citigroup Neutral
2015-06-01 개시 Citigroup Buy
2015-06-01 개시 JP Morgan Overweight
모두보기

Atyr Pharma Inc 주식(ATYR)의 최신 뉴스

pulisher
10:58 AM

aTyr Pharma Inc put volume heavy and directionally bearish - TipRanks

10:58 AM
pulisher
Jul 28, 2025

aTyr Pharma Stock Faces Market Scrutiny Amid Financial Challenges - StocksToTrade

Jul 28, 2025
pulisher
Jul 28, 2025

Is it the right time to buy aTyr Pharma Inc. stockAchieve breakthrough gains with smart trades - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about aTyr Pharma Inc.Free Consultation - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are aTyr Pharma Inc. company’s key revenue driversGet daily updates on the hottest stocks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

How does aTyr Pharma Inc. generate profit in a changing economyRapid wealth accumulation - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What makes aTyr Pharma Inc. stock price move sharplyUnlock powerful stock screening techniques - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What is aTyr Pharma Inc. company’s growth strategyBuild a portfolio with strong long-term growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How volatile is aTyr Pharma Inc. stock compared to the marketUnstoppable trading performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Is aTyr Pharma Inc. a good long term investmentUnprecedented market success - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Does aTyr Pharma Inc. stock pay reliable dividendsHigh-performance investment picks - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

RNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP TherapeuticsResearchAndMarkets.com - FinancialContent

Jul 25, 2025
pulisher
Jul 23, 2025

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga

Jul 23, 2025
pulisher
Jul 23, 2025

aTyr Pharma Soars 11.26% on Phase 3 Study Completion - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

aTyr Pharma stock holds Buy rating as Phase 3 trial completes - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about aTyr Pharma Inc. stockMarket-leading capital gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

What drives aTyr Pharma Inc. stock priceMarket-beating returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

First-Ever Global Phase 3 Trial for Sarcoidosis Treatment Reaches Major Milestone with 268 Patients - Stock Titan

Jul 22, 2025
pulisher
Jul 19, 2025

aTyr Pharma Reaches US$515m Market Cap Benefiting Insider Stock Buying - simplywall.st

Jul 19, 2025
pulisher
Jul 18, 2025

aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jul 18, 2025
pulisher
Jul 18, 2025

RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding - GlobeNewswire Inc.

Jul 18, 2025

Atyr Pharma Inc (ATYR) 재무 분석

Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Atyr Pharma Inc 주식 (ATYR) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Broadfoot Jill Marie
Chief Financial Officer
Feb 04 '25
Sale
3.78
1,254
4,740
31,763
DENYES NANCY
General Counsel
Feb 04 '25
Sale
3.78
899
3,398
26,555
$76.39
price up icon 8.67%
$37.37
price up icon 0.88%
$104.04
price up icon 2.27%
$26.87
price down icon 2.34%
$110.46
price down icon 2.07%
biotechnology ONC
$305.19
price up icon 3.74%
자본화:     |  볼륨(24시간):